Acrux Limited (AU:ACR)
ASX:ACR
Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$6.79M
Enterprise ValueAU$7.62M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding522,284,360
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing-based Revenue ModelAcrux's revenue model relies on licensing, producing royalty and milestone streams tied to partner sales. This asset-light approach reduces manufacturing risk and capital intensity, allowing scalability and predictable recurring cash inflows as partner products penetrate markets, supporting long-term durability if partner execution holds.
Strong Recent Revenue GrowthMaterial recent revenue acceleration signals improving commercial traction or milestone recognition, which can translate into sustainably higher royalty bases. If revenue growth reflects durable uptake or expanded licensing, it improves the company's ability to cover fixed costs and supports margin expansion over the medium term, aiding cash conversion.
Improved Gross Margin And FCF TrendA surge in gross margin and a modest improvement in free cash flow in 2025 indicate that revenue is increasingly translating to high-margin, low-cost income (typical of royalties). Over months, this improves operational leverage and the potential to move toward profitability if growth continues and operating expenses are controlled.
Bears Say
High Financial LeverageA debt-to-equity of 3.55 denotes substantial leverage that reduces financial flexibility, raises interest obligations, and elevates refinancing risk. For a licensing-focused biotech with variable royalty timing, high leverage can force financing at unfavorable terms and constrain investment in business development over the medium term.
Persistent Negative ProfitabilityOngoing negative net and EBIT margins show the company has yet to convert revenue into sustainable profits. Continued operating losses limit retained earnings and investor flexibility, requiring reliance on external funding or partner payments; this undermines long-term resilience unless margins improve consistently.
Negative Operating Cash FlowNegative operating cash flows and limited free-cash generation indicate the business is burning cash to operate. Over several months this squeezes liquidity, increases dependence on debt or equity raises, and complicates funding of R&D or commercial support, particularly given the company's elevated leverage and episodic royalty timing.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$6.79M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 77 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 522,284,360 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---